Mohan S, Baylink D J
Musculoskeletal Diseases Center, JLP Veterans Administration Medical Center, 11201 Benton St, Loma Linda, California 92357, USA.
J Endocrinol. 2005 Jun;185(3):415-20. doi: 10.1677/joe.1.06141.
Although it is well established that there is considerable inter-individual variation in the circulating levels of IGF-I in normal, healthy individuals and that a genetic component contributes substantially to this variation, the direct evidence that inter-individual variation in IGF-I contributes to differences in peak bone mineral density (BMD) is lacking. To examine if differences in IGF-I expression could contribute to peak BMD differences, we measured skeletal changes at days 23 (prepubertal), 31 (pubertal) and 56 (postpubertal) in mice with haploinsufficiency of IGF-I (+/-) and corresponding control mice (+/+). Mice (MF1/DBA) heterozygous for the IGF-I knockout allele were bred to generate +/+ and +/- mice (n=18-20 per group). Serum IGF-I was decreased by 23% (P<0.001) in mice with IGF-I haploinsufficiency (+/-) group at day 56 compared with the control (+/+) group. Femoral bone mineral content and BMD, as determined by dual energy X-ray absorptiometry, were reduced by 20% (P<0.001) and 12% respectively in the IGF-I (+/-) group at day 56 compared with the control group. The peripheral quantitative computed tomography measurements at the femoral mid-diaphysis revealed that periosteal circumference (7%, P<0.01) and total volumetric BMD (5%, P<0.05) were decreased significantly in the +/- group compared with the +/+ group. Furthermore, serum IGF-I showed significant positive correlations with both areal BMD (r=0.55) and periosteal circumference (r=0.66) in the pooled data from the +/+ and +/- groups. Our findings that haploinsufficiency of IGF-I caused significant reductions in serum IGF-I level, BMD and bone size, together with the previous findings, are consistent with the notion that genetic variations in IGF-I expression could, in part, contribute to inter-individual differences in peak BMD among a normal population.
尽管正常健康个体中胰岛素样生长因子-I(IGF-I)的循环水平存在显著的个体间差异,且遗传因素在很大程度上导致了这种差异,这一点已得到充分证实,但仍缺乏直接证据表明IGF-I的个体间差异会导致峰值骨密度(BMD)的差异。为了研究IGF-I表达的差异是否会导致峰值BMD的差异,我们在IGF-I单倍体不足(+/-)的小鼠和相应的对照小鼠(+/+)中,测量了第23天(青春期前)、第31天(青春期)和第56天(青春期后)的骨骼变化。将携带IGF-I基因敲除等位基因的杂合子小鼠(MF1/DBA)进行繁殖,以产生+/+和+/-小鼠(每组n = 18 - 20只)。与对照组(+/+)相比,IGF-I单倍体不足(+/-)组小鼠在第56天时血清IGF-I降低了23%(P < 0.001)。与对照组相比,IGF-I(+/-)组在第56天时通过双能X线吸收法测定的股骨骨矿物质含量和BMD分别降低了20%(P < 0.001)和12%。股骨中骨干的外周定量计算机断层扫描测量显示,与+/+组相比,+/-组的骨膜周长(7%,P < 0.01)和总体积BMD(5%,P < 0.05)显著降低。此外,在来自+/+和+/-组的汇总数据中,血清IGF-I与面积BMD(r = 0.55)和骨膜周长(r = 0.66)均呈显著正相关。我们的研究结果表明,IGF-I单倍体不足导致血清IGF-I水平显著降低、BMD和骨大小减小,与之前的研究结果一致,这支持了IGF-I表达的遗传变异可能在一定程度上导致正常人群中峰值BMD个体间差异的观点。